Overall survival (OS) in patients with relapsed and refractory acute myeloid leukaemia treated with vosaroxin or placebo in combination with cytarabine, for all patients (A), censored for allogeneic stem cell transplant (alloSCT) (B), patients aged ≥60 years vs <60 years (C, D); and early relapsed vs late relapsed vs refractory patients (E, F, G).
CI= confidence interval; HR=hazard ratio; Pla/Cyt=placebo+cytarabine; Vos/Cyt=vosaroxin+cytarabine.